A RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY COMPARING THE EFFECT OF ONCE-WEEKLY DULAGLUTIDE WITH ONCE-DAILY LIRAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES (AWARD-6: ASSESSMENT OF WEEKLY ADMINISTRATION OF LY2189265 IN DIABETES-6)

A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes (AWARD-6)

Approval Date: 8/23/2012

Principal Investigator: Wendy Miller, MD

The purpose of the study is to assess the benefits and risks of once-weekly dulaglutide compared to once-daily liraglutide in participants with type 2 diabetes who have inadequate glycemic control on metformin.

Eligibility:

Each study has its own guidelines to determine who can participate, called "eligibility criteria", with only the study doctor able to assess whether you meet all of the eligibility criteria.   

More information can be found at  http://clinicaltrials.gov/show/NCT01624259.

Contact Person:
Catherine Coleman, Research Coordinator
248-655-5865

Status of Clinical Trial:
open and enrolling